AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs - Ownership and Business Overview

Life ScienceCompany

AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs Ownership

Who owns AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs?

AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs is owned by AC Immune SA. It was acquired on July 27, 2021.

AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs Business Overview

Where is AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs headquartered?

AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs is headquartered in Vienna, Austria.

What sector is AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs in?

AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs is a life science company.

Life Science M&A Summary in 2021

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.

Join Mergr to view all 387 acquisitions of life science companies in 2021, including 43 acquisitions by private equity firms, and 344 by strategics.

AFFiRiS - Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs

Vienna, 1030
Austria,

AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs are clinically validated active vaccine candidates for the treatment of Parkinson's disease. AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein Programs is based in Vienna, Austria.


Company Summary

SECTOR

Life Science

 Subscribe to unlock this and 201,882
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for AFFiRiS - Specific Active Immunotherapy anti-alpha-synuclein Programs

Life Science Companies , Austria Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for Austria Companies

Largest Austria Companies , Acquisitive Austria Companies , Recently Acquired Austria Companies , Recently Sold Austria Companies , Private Austria Companies , Public Austria Companies , Acquired Austria Companies , PE Backed Austria Companies
Mergr

Product

Company

Legal